SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending following earnings, with the community debating the impact of increased AI spending and a one-time tax charge despite strong revenue numbers.  Bulls view the dip as a buying opportunity, expecting a quick recovery, while bears are concerned about Meta's aggressive investment strategy and potential impact on profitability. Technical levels and potential support zones are being closely watched for signs of a bottom.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending following news of significant antimony mining developments in Montana and an increase to its FY2026 revenue guidance, driving optimism among investors. Community discussions revolve around the potential for a short squeeze and the company's strategic positioning as a key antimony supplier outside of China. Some investors are also speculating about a potential hostile takeover bid for Larvotto Resources.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet's stock is trending as strong AI demand and advertising growth drove its Q3 revenue above expectations, prompting increased capital expenditure forecasts and community excitement. Investors are reacting positively to Alphabet's favored cash flow strategy and AI investments, while some analysts are predicting further gains. Community members are actively discussing the stock's potential to reach new price levels and its long-term investment value.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending due to concerns about slowing growth and reduced guidance, sparking debate about its valuation and future prospects. Community discussions center on whether the brand is losing its value proposition amid rising prices and inconsistent portions, with some criticizing the CEO's handling of the situation. Investors are weighing whether the dip presents a buying opportunity or signals deeper issues within the company and the broader consumer discretionary sector.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as the stock price reaches new highs, driven by optimism surrounding AI and cloud services. Community members are discussing earnings expectations and debating whether the stock is overbought. Some are highlighting a new partnership to restart a nuclear power plant.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is trending due to recent earnings and the Versant spin-off, with community discussion focusing on broadband subscriber losses versus growth in wireless and theme parks. Some believe the company is undervalued, especially with a potential acquisition of WBD, while others are concerned about cord-cutting and competition. Community members are actively weighing the impact of these factors on the stock's future performance.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending with analysts reiterating overweight ratings and raising price targets, while the community discusses solid sentiment after earnings. The stock's movement is also influenced by broader tech sector trends, with attention on cloud revenue growth and AI investments. Some traders are weighing MSFT against other tech giants like META and GOOGL.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending due to strong Q3 earnings, driven by high demand for weight loss drugs Mounjaro and Zepbound, which beat revenue expectations and raised the FY25 guidance. The community is focused on the impact of this GLP-1 momentum, potential FDA approvals, and the company's strategic partnerships in AI, viewing LLY as a leader in the pharmaceutical sector.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to a mix of tech earnings and anticipation surrounding a potential trade agreement between the U.S. and China. Community discussion revolves around whether positive outcomes from the Trump-Xi meeting are already priced in, especially with mixed reactions to earnings from major tech companies like Meta and Microsoft. Concerns about AI spending and its impact on company financials are also contributing to market volatility.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox ($RBLX) is trending due to mixed reactions to company performance and future outlook. While some celebrate strong user growth and engagement, others express concerns about profitability, valuation, and safety on the platform. Community discussions also involve potential analyst upgrades and potential impact from institutional investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The payment was in connection with the dosing of the first patient in a late-stage registrational trial of Ziftomenib.</li><li>Kura Oncology and Kyowa Kirin had entered into a deal in November 2024 to jointly develop and commercialize Ziftomenib. &nbsp;</li></ul>Kura Oncology (KURA) said on Friday that it received a $30 million milestone payment under its collaboration agreement with Japan-based Kyowa Kirin, inked late last year.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/24/3172720/35186/en/Kura-Oncology-Receives-30-Million-Development-Milestone-Payment-in-Ziftomenib-AML-Program-with-Kyowa-Kirin.html">payment</a> was in connection with the dosing of the first patient in a late-stage registrational program of Ziftomenib evaluating the drug in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed acute myeloid leukemia with certain conditions. The companies announced the launch of the said trial on September 29.The program includes two late-stage trials intended to support potential U.S. accelerated approval and full approval. The trial is expected to enroll patients at up to 200 sites worldwide.According to Kura, the late-stage program is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings.<h2 class="st-heading-2">Terms Of The Deal</h2>Kura Oncology and Kyowa Kirin had entered into a deal in November 2024 to jointly develop and commercialize Ziftomenib. Under the agreement, Kura is eligible to receive up to $1.2 billion in total milestone payments, including near-term milestone payments. &nbsp;As per the terms of the agreement, Kura will lead development, regulatory, and commercial strategy in the U.S. while Kyowa leads it outside the U.S.<a href="https://stocktwits.com/symbol/KURA">KURA shares</a> traded 6% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around KURA stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.KURA stock is up by over 4% this year but down by about 49% over the past 12 months.Read also:<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/jp-morgan-to-let-clients-use-bitcoin-ethereum-as-loan-collateral-by-year-end/cLGJVtKR3sH"> JPMorgan To Let Clients Use Bitcoin, Ethereum As Loan Collateral By Year-End: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement

The payment was in connection with the dosing of the first patient in a late-stage registrational trial of Ziftomenib.

Equity

<ul class="summary-bullets"><li>Viking on Thursday reported a third-quarter loss per share of $0.81, compared to the expected loss of $0.7 per share.&nbsp;</li><li>Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating.</li><li>The analyst noted that two of the company’s late-stage trials for subcutaneous VK2735 are enrolling ahead of schedule.</li></ul>Viking Therapeutics (VKTX) received a price target hike from Morgan Stanley on Thursday on the heels of positive third-quarter updates.&nbsp;Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating. The new price target represents a potential upside of 225% from the stock’s closing price on Wednesday.<h2 class="st-heading-2">Morgan Stanley’s Take</h2>The analyst noted that two of the company’s late-stage trials for subcutaneous VK2735 are enrolling ahead of schedule, and the management plans to meet with the U.S. Food and Drug Administration for oral VK2735 in Q4 with a late-stage study start targeted soon after. The firm is "encouraged by swift execution across programs," the analyst added.Viking CEO Brian Lian said on Thursday that the company is expected to complete enrollment in the VANQUISH-1 study later this quarter, with VANQUISH-2 to follow in the first quarter of 2026. The VANQUISH late-stage program, including trials of Viking's subcutaneous formulation of VK2735 in patients with obesity and obesity with type 2 diabetes, was initiated in the second quarter.Viking on Thursday <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update-302591893.html">reported</a> a third-quarter loss per share of $0.81, compared to the expected loss of $0.7 per share, according to data from Fiscal AI. The company pinned the rise in net loss for the three months ended Sept. 30, 2025, to the increase in research and development expenses.The company ended the quarter with a cash position of $715 million, which it believes provides sufficient resources to develop VK2735 through the VANQUISH clinical trials and to continue development of additional clinical programs in its pipeline.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/VKTX">VKTX shares</a> soared 7% at the time of writing. On Stocktwits, retail sentiment around VKTX jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels. Retail chatter around the stock rose 197% over the past 24 hours, as of Thursday morning, according to Stocktwits data.<figure class="image"><img style="aspect-ratio:620/63;" src="data:image/png;base64,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" width="620" height="63" alt="VKTX's Sentiment Meter and Message Volume as of 10:06 a.m. ET on Oct. 23, 2025 | Source: Stocktwits"><figcaption>VKTX's Sentiment Meter and Message Volume as of 10:06 a.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>VKTX stock is down by 16% this year and by 44% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-raises-full-year-revenue-guidance-ahead-of-earnings/cLG4ilnR3rG">Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Soars After Morgan Stanley’s Price Target Implies A Potential 225% Upside

Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating.

Buy, Hold and Build Wealth: ETFs for Long-Term Investors

Market volatility is rising but buy-and-hold ETFs like SPY, VOO and VTI offer investors diversification and long-term resilience.

Anavex Life Sciences (AVXL) on Thursday said that its investigational drug achieved its primary endpoint in a mid-stage trial and demonstrated safety and tolerability in adults with Schizophrenia.Shares of the company soared 9% in Thursday’s pre-market session.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160275/29248/en/Anavex-Life-Sciences-Announces-Positive-Topline-Results-from-Phase-2-Study-of-ANAVEX-3-71-for-the-Treatment-of-Schizophrenia.html">said</a> that the safety profile of ANAVEX3-71 was consistent with previous studies in healthy volunteers, and no serious treatment-emergent adverse events were reported in the study.The company is evaluating the drug in the treatment of Schizophrenia, a persistent and often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide. According to Anavex, the illness impacts 2.8 million people in the U.S. alone.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume stayed at ‘high’ levels.Anavex also said on Thursday that encouraging trends were observed in biomarkers of Schizophrenia in the study that support continued development. This includes a reduced glial fibrillary acidic protein in patients receiving ANAVEX3-71 compared to placebo.GFAP is a marker of neuroinflammation, and a reduction in it suggests a potential disease-modifying effect that may become more pronounced with longer treatment durations, the company said.The company on Thursday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160281/29248/en/Anavex-Life-Sciences-Announces-Successful-Development-of-Once-Daily-Oral-Tablet-Formulation-for-the-ANAVEX-3-71-Program.html">announced</a> the successful development of a once-daily oral tablet formulation for the ANAVEX3-71 program. The tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, enabling once-daily dosing, it added.AVXL stock is down 16% this year but up approximately 59% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-slashes-full-year-delivery-guidance-after-drop-in-q3-figures/chCrfpbR3OH">Rivian Slashes Full-Year Delivery Guidance After Drop In Q3 Figures</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update

The company said that its investigational drug for Schizophrenia achieved its primary endpoint in a mid-stage trial.

Enanta Pharmaceuticals (ENTA) on Monday announced that its mid-stage trial evaluating the efficacy and safety of Zelicapavir in outpatient adults with acute Respiratory Syncytial Virus (RSV) infection who are at high risk of complications failed to meet the primary endpoint.Shares of the company, however, rose 58% by Monday afternoon. Notably, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-its">stated</a> that a clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms was observed for Zelicapavir compared to placebo, with a benefit of 2.2 days for the overall efficacy population and 6.7 days for patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or aged 75 and older.A lower hospitalization rate was observed for patients treated with Zelicapavir compared to placebo, and Zelicapavir demonstrated a robust antiviral effect, it added.The study, however, failed in its primary endpoint of lowering the time to resolution of lower respiratory tract disease symptoms to mild. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ENTA">ENTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_1_22_50_PM_png_995d6b1542.webp" alt="ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="576" height="65"><figcaption>ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user cheered the rally.<stembedurl>https://stocktwits.com/JL_TradeZ/message/630342393</stembedurl>Another noted that though the trial missed the primary endpoint, the rest of the data “looks great.”<stembedurl>https://stocktwits.com/heyupikachu1821/message/630357384</stembedurl>Enanta said on Monday that Zelicapavir demonstrated a favorable safety profile in the trial and was well-tolerated. The goal of the study was to inform the design of a late-stage trial, including populations and endpoints, and no adverse events led to treatment discontinuation or study withdrawal in the Zelicapavir group.“We believe the totality of these data provides strong rationale for further clinical advancement of zelicapavir. Importantly, we identified multiple potential registrational endpoints for a Phase 3 trial,” said Chief Medical Officer Scott T. Rottinghaus.RSV is a common respiratory virus that infects the lungs and respiratory tract. Older adults are at significantly increased risk of severe illness due to the natural weakening of the immune system with age.ENTA stock has more than doubled this year and gained by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kala-bio-stock-plunges-after-experimental-drug-fails-study/chDuP3wR3Ja">Kala Bio Stock Just Plunged 89% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, capsules are seen in a hand dressed in a medical glove with the Enanta Pharmaceuticals logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.

uniQure N.V. (QURE) on Wednesday said that a high dose of its experimental gene therapy AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.Shares of the company rose a whopping 161% in the pre-market session at the time of writing.Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities, and cognitive decline. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.uniqure.com/investors-media/press-releases">stated</a> that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS), a comprehensive assessment tool used in clinical trials for Huntington's disease. The company also identified a statistically significant 60% slowing of disease progression as measured by Total Functional Capacity (TFC) at 36 months.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QURE">QURE stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.uniQure on Wednesday said that the therapy was generally well-tolerated in the trial with a manageable safety profile. No new drug-related serious adverse events have been observed from December 2022 to the end of June 2025, it added.Chief Medical Officer Walid Abi-Saab said that the company is looking forward to discussing the data with the U.S. Food and Drug Administration at a meeting later this year. The company plans to submit an application for approval of AMT-130 to the FDA in the first quarter of 2026 and anticipates launching it in the U.S. later in the same year.According to the company, there are currently no approved therapies to slow the progression of Huntington’s disease. The disease affects approximately 75,000 people in the U.S., EU, and the U.K., it added.QURE stock is down by 23% this year but has risen approximately 166% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-pharmaceuticals-investigational-drug-for-rare-genetic-disorder-fails-in-late-stage-study/chD1Gf0R33B">Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

QURE Stock Jumped A Whopping 161% Pre-Market – Here’s What Happened

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 

ETFs to Gain as Inflation Edges Higher in August

Inflation rose in August, but jobless claims rose, too, shaping Fed rate cut odds and boosting the appeal of large-cap blend ETFs like ITOT, EDOW and IVV. 

AI server provider Super Micro Computer Inc (SMCI) saw a 361% increase in&nbsp;Stocktwits user message count in the last 24 hours, driven by buzz around its new partnership with AI infrastructure firm Digi Power X and growing excitement about the broader AI market.<a href="https://stocktwits.com/symbol/SMCI">Super Micro Computer stock</a> inched 0.4% higher in Tuesday’s premarket. Retail sentiment around the stock improved to ‘bullish’ (71/100) from ‘neutral’ territory the previous day. Message volume jumped to ‘extremely high’ (76/100) from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:965/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_29_081246_png_01352b2a04.webp" alt="SMCI’s Sentiment Meter and Message Volume as of 08:20 a.m. ET on July 29, 2025 | Source: Stocktwits" width="965" height="124"><figcaption>SMCI’s Sentiment Meter and Message Volume as of 08:20 a.m. ET on July 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said the stock is catching up to its peers.<stembedurl>https://stocktwits.com/rp12812/message/622821002</stembedurl>A bullish user noted that Super&nbsp;Micro is among the most undervalued AI stocks in the U.S.<stembedurl>https://stocktwits.com/cryptokzer/message/622818895</stembedurl>Digi Power X said it aims to expand its ARMS 200 data center platform in partnership with Super Micro Computer to deliver 40 megawatts (MW) of essential computing power and 55 MW overall at its main facility in Alabama, enough to handle around 10,240 Nvidia GPUs (graphic processing units).Super Micro designs and manufactures servers, storage, and networking systems in-house across the U.S., Taiwan, and the Netherlands.&nbsp;"Combined with our Supermicro partnership and Tier 3-certified design, we are positioning ourselves to scale the ARMS 200 from first deployments expected later this year into a full-fledged AI infrastructure network,” Digi said CEO Michel Amar.The company earlier revealed it had placed an order with Super Micro for systems powered by Nvidia B200 GPUs to kick off the ARMS 200 platform.&nbsp;The first rollout is expected to begin in the fourth quarter (Q4) of 2025.Super Micro stock surged over 10% on Monday following a similar upward trend seen among other semiconductor companies.The rally in chip stocks on Monday was boosted by a Financial Times&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stocks-making-the-biggest-moves-today-july-28/choeuX1R5xB">report</a> that the U.S. has paused certain tech export restrictions to China for the time being.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/this-chip-software-provider-witnessed-a-whopping-3-400-jump-in-retail-chatter-over-24-hours-here-s-why/cho9MXgR5U8">This Chip Software Provider Witnessed A Whopping 3,400% Jump In Retail Chatter Over 24 Hours: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Super Micro Computer, Inc. logo is seen displayed on a smartphone screen. 

This Server Giant Is Sprinting Into The AI Era: Here’s What’s Fueling Retail Interest

Super Micro Computer will help AI infrastructure provider Digi Power X expand its ARMS 200 data center platform in Alabama.

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) traded 22% lower in Thursday’s pre-market session after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001430306/000199937125007625/tnxp-8k.htm">announced</a> share sale plans on Wednesday.The company entered into a sales agreement with A.G.P./Alliance Global Partners, serving as the sales agent, under which it intends to sell $150 million of shares of its common stock.Tonix also entered into a purchase agreement with Lincoln Park Capital Fund, LLC, under which the company will have the right to sell up to $75 million of newly issued shares of common stock to the firm.&nbsp;The proceeds from the purchase agreement are expected to be used for working capital and general corporate purposes.The biotech company focused on developing therapies for pain management is currently looking forward to a potential approval of TNX-102 SL for the treatment of fibromyalgia. FDA’s decision on its application for approval is due by Aug. 15, and the company is anticipating a product launch in the fourth quarter of 2025.A Stocktwits user expressed skepticism at the potential share dilution.<stembedurl>https://stocktwits.com/Bibby12/message/617653759</stembedurl>Another user highlighted the company’s debt-free status and opined that the move is not a desperate measure.<stembedurl>https://stocktwits.com/WARBUD/message/617627746</stembedurl>The company has cash and cash equivalents of $131.7 million as of the first quarter, which it said would be sufficient to fund operations into the second quarter of 2026Retail sentiment around Tonix on Stocktwits rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume jumped from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_7_30_16_AM_png_3b8ab0bc3f.webp" alt="TNXP's Sentiment Meter and Message Volume as of 7:30 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="628" height="62"><figcaption>TNXP's Sentiment Meter and Message Volume as of 7:30 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>According to data from Koyfin, the two analysts covering the stock rate it a ‘Buy’. The stock has an average price target of $61.67, representing an upside of over 60% from current trading levels.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is up by about 20% this year but down by approximately 66% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/boeing-stock-tumbles-after-air-india-787-crashes-in-ahmedabad-with-242-onboard/chlXwJWRb6A">Boeing Stock Tumbles After Air India 787 Crashes In Ahmedabad With 242 Onboard</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Tonix Pharma Stock Plunges 20% Pre-market On Share Sale Announcement, But Retail’s Not Pessimistic

The proceeds from the purchase agreement are expected to be used for working capital and general corporate purposes.

Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

BlackRock Institutional Trust Company N.A. - iShares Core S&P Total U.S. Stock Market ETF

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

ITOT
iShares Core S&P Total U.S. Stock Market ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ITOT News

ITOTiShares Core S&P Total U.S. Stock Market ETF